Waltham, Mass., June 15th, 2026: ZOLYMBUS™ (bimatoprost ophthalmic gel) 0.01%, a new preservative-free gel formulation for glaucoma management, is set to launch in the United States, marking a significant addition to the treatment options available to Eye Care Professionals and patients living with glaucoma.
Glaucoma remains one of the leading causes of irreversible vision loss worldwide, requiring long-term treatment adherence and ongoing patient confidence in therapy. ZOLYMBUS was developed to help address these critical challenges by combining efficacy, safety, tolerability, and convenience in a preservative-free gel formulation designed to support both physician and patient needs.
“With the launch of ZOLYMBUS, we are introducing more than a new treatment option — we are delivering an innovative solution designed to improve the experience of glaucoma management for both patients and providers,” said Rob Shilton, Head of Marketing, THEA US. “This launch reflects our continued commitment to advancing ophthalmic care through meaningful innovation and patient-focused therapies.”
Backed by strong product availability and patient access initiatives, ZOLYMBUS enters a dynamic and growing ophthalmology market with a differentiated profile that positions it as a compelling new option for glaucoma care. The product also strengthens the organization’s leadership in preservative-free ophthalmic therapies and reinforces its commitment to providing Eye Care Professionals with innovative treatment solutions.
The launch of ZOLYMBUS is expected to further expand engagement with clinicians throughout the U.S., support collaboration with influential ophthalmology thought leaders, and enhance the company’s growing reputation within the eye care community. “Our team is energized by the opportunity ahead,” added Shilton. “Through strong partnerships with Eye Care Professionals and a continued focus on clinical excellence, we believe ZOLYMBUS has the potential to make a meaningful impact in glaucoma care across the United States.”
About ZOLYMBUS
ZOLYMBUS is an innovative preservative-free gel formulation which is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.1 Designed and developed with a focus on efficacy, tolerability, safety, and convenience, ZOLYMBUS aims to support long-term treatment adherence while addressing important needs for both patients and Eye Care Professionals.
To learn more about ZOLYMBUS, please visit www.ZOLYMBUS.com.
About THEA PHARMA INC. (“THEA US”)
THEA US is committed to advancing eye care through innovative, patient-focused ophthalmic therapies. As part of the global Théa Group, a leader in preservative-free ophthalmic products, THEA US partners closely with Eye Care Professionals to deliver high-quality treatment solutions that support patient safety, comfort, and long-term therapeutic outcomes. With a strong focus on innovation, clinical excellence, and access to care, THEA US continues to expand its portfolio to address the evolving needs of patients and providers across the United States.
To learn more about Thea Pharma, Inc., visit https://theapharmainc.com.
ZOLYMBUS Important Safety Information
INDICATIONS AND USAGE
ZOLYMBUS™ (bimatoprost ophthalmic gel) 0.01%, is a prostaglandin analog indicated for the reduction of elevated intraocular pressure in patients with open-angle glaucoma or ocular hypertension.
IMPORTANT SAFETY INFORMATION
CONTRAINDICATIONS
Known hypersensitivity to bimatoprost or any other ingredients in this product.
WARNINGS AND PRECAUTIONS
Bimatoprost may cause changes to pigmented tissues. Most frequently reported changes are increased pigmentation of the iris, periorbital tissue (eyelid), and eyelashes. Pigmentation is expected to increase as long as bimatoprost is administered. Iris pigmentation is likely to be permanent. Eyelid skin darkening and eyelash changes may be reversible.
Bimatoprost may cause gradual change to eyelashes including increased length, thickness, and number of lashes. These changes are usually reversible upon discontinuation of treatment.
Prostaglandin analogs, including bimatoprost, have been reported to cause intraocular
inflammation. ZOLYMBUS should be used with caution in patients with active intraocular inflammation (e.g., iritis/uveitis) because inflammation may be exacerbated.
Macular edema, including cystoid macular edema, has been reported during treatment with bimatoprost ophthalmic products. ZOLYMBUS should be used with caution in aphakic patients, in pseudophakic patients with a torn posterior lens capsule, or in patients with known risk factors for macular edema.
Contact lenses should be removed prior to the administration of ZOLYMBUS and may be reinserted 15 minutes after administration.
ADVERSE REACTIONS
Most common adverse reactions (≥10%) are conjunctival hyperemia
(14%) and eye irritation (11%).
Please visit www.zolymbus.com/PI for the full Prescribing Information.
U.S. Media Inquiries Please Contact: marketing.us@theapharma.com
REFERENCE: 1. ZOLYMBUS [prescribing information]. Thea Pharma Inc.; 2025.
PRC-EN-3079-V2 06.2026
more news
LEXINGTON, Massachusetts – March 3, 2023 – Thea Pharma, Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Théa, dedicated to the research, development, and commercialization of ophthalmic products, announced the presentation of Phase III data on IYUZEH (latanoprost ophthalmic solution) 0.005% by Jason Bacharach, MD at the 2023 American Glaucoma Society (AGS) [...]
IYUZEH™ (latanoprost ophthalmic solution) 0.005% is the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA) in the United States LEXINGTON, Massachusetts – December 14, 2022 – Thea Pharma, Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Laboratoires Théa, dedicated to the research, development and commercialization of ophthalmic products, [...]
IYUZEH™ (latanoprost ophthalmic solution) 0.005%, the first and only preservative-free formulation of latanoprost, the most prescribed prostaglandin F2α analogue (PGA), is now available in the U.S.
The Glaucoma Foundation, The Intrepid Eye Society, National Medical Association Ophthalmology Section, and Real World Ophthalmology Unite with Thea to Help Preserve Patient Eye Health WALTHAM, Mass., May 30, 2023 /PRNewswire/ — Thea Pharma Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent ophthalmic-focused pharmaceutical company, Laboratoires Théa, today announced the launch of the Preservative Freedom Coalition to raise awareness of unmet [...]
Thea Portfolio of Products Acquired from Akorn are not Affected by this Recall WALTHAM, Mass., April 28, 2023 /PRNewswire/ — Thea Pharma Inc. (“Thea”), the U.S. subsidiary of Europe’s leading independent pharmaceutical company, Laboratoires Théa, dedicated to the research, development, and commercialization of ophthalmic products, is responding to the recent statement related to the Akorn [...]
